Compound class:
Synthetic organic
Comment: Laniquidar (R101933) is a third generation inhibitor of the ATP-binding cassette transporter P-glycoprotein (P-gp; ABCB1) [1-2]. P-gp is a drug transporter and efflux pump that can promote resistance to drugs, including chemotherapeutics. Pharmacologic inhibition of P-gp is an established strategy that is being investigated to block this resistance mechanism in cancers [1].
|
|
References |
1. Lai JI, Tseng YJ, Chen MH, Huang CF, Chang PM. (2020)
Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics. Front Oncol, 10: 561936. [PMID:33312947] |
2. Werle M, Takeuchi H, Bernkop-Schnürch A. (2008)
New-generation efflux pump inhibitors. Expert Rev Clin Pharmacol, 1 (3): 429-40. [PMID:24422696] |